A One-Time-Only Invitation

The invitation I’m about to share is a big exception to our typical offers.

It’s the final thing I can do to recognize the way Ken represented our company by coming forward with his story…

And, most importantly, to make sure you don’t miss the biggest gains from likely the most important investing story of the next decade.

I’m inviting you to join Dave Lashmet’s elite research letter, Stansberry Venture Technology.

Say “yes” and you’ll immediately receive:

• How to Profit – and Keep Profiting – From the GLP-1 Revolution
• What’s Next After GLP-1: The Innovations with Upside as High as 1,000%

Of course, most importantly, you’ll begin receiving Stansberry Venture Technology each month going forward.

Along with the entire archives of every issue Dave’s ever published…

And his entire, live model portfolio today, with over 40 recommended positions.

Including everything you need to know to profit – and keep profiting – from the GLP-1 drug revolution… and all the follow-on developments I’ve mentioned today.

And many more new ideas that are just beginning to emerge… ideas that Dave is reporting years ahead of anyone else… just like investing in the “What Comes Next” stories of the digital revolution in the earliest days of the internet.

Stansberry Venture Technology is our highest-end research… and has always held a special place among everything we publish.

Although anyone can subscribe (at full price)… the nature of these small, early-stage, and virtually unknown opportunities means that we rarely talk about this research – much less promote it with a discount.

It normally costs $5,500 for a single year of access.

That’s frankly a pittance for specialized research of this caliber.

Dave’s work is based around the same ideas as an early-stage venture capital fund. (One that would likely require $100,000 or more minimum investment… then charge tens of thousands in fees while locking up your capital for years.)

Just in the last couple years, he could have shown you gains of 1,139%… 691%… 1,466%… and many more of well over 100%.

Those are some of the biggest gains across all of our research… and they’re one reason why we rarely discount this research at all.

But to honor the commitment I’ve made today – to you and to my colleague Ken – I’m inviting you in for the single lowest first-year price we’ve EVER offered to anyone.

Just $2,000 today if you say yes below, on this page.

As I mentioned, you can keep this discount every year, from now on, for as long as you choose to remain a subscriber.

It won’t change, no matter how much others may pay in the future.

And while these developments will be unfolding for years to come, I have NO doubt that by this time next year, you could be sitting on some of the biggest gains of your investing life.

Plus... you'll also get another bonus I haven't mentioned yet.

Say “yes” and you’ll get instant access to TWO video presentations from our private, closed-door Alliance conference.

It costs thousands just to get in the door – on top of a $30,000 Alliance subscription.

And it's where editors share some of their very best ideas.

You'll get:

• Dave’s full, 30-minute presentation about four NEW opportunities you haven’t heard about yet today.
  
  They are all companies that could help millions beat a disease killing more people than breast and prostate cancer combined.
  
  Dave thinks they’re all “buys” today – with triple-digit potential upside.
• Plus a second, panel presentation featuring Dave and SIX other top Stansberry Research editors – including Brett Eversole, Dan Ferris and Greg Diamond – all sharing their very best lower-risk growth ideas for 2024.
  
  Dave’s pick has nothing to do with biotech...
  
  Instead, it’s a business that he predicts could become the world’s SOLE supplier of a crucial component – essentially the lifeblood – across 169 industries.
  
  He sees 400% potential upside.  

Each of these videos are valued at $1,250.

But you'll get instant access to both – at NO extra charge – when you say "yes" below.

That's an additional $2,500 value, yours free.

That’s worth more – by itself – than your cost to get started today. And it’s a completely free bonus… on top of everything else I’ve already mentioned to make this deal even better for you, when you accept below.

Keep in mind: Because of the nature of this offer and this highly specialized research, we cannot offer cash refunds.

But you can get started today and take the next 30 days to look everything over. If you’re unhappy for any reason, you can claim back every penny you paid as Stansberry Credit – and keep the reports and research you’ve already received, with our compliments.

Normally, I’d consider this offer a significant risk to our business.

But I’m not worried in this case, for one simple reason.

I seriously doubt that a single reader who sees Dave’s detailed research and gets started with a handful of his ideas will change their mind.

The opportunity is yours for the taking.

But I can only make this available for a short time – and we’ll likely never share an offer this good again.

You’ll get instant access to the brand-new special reports I’ve mentioned:

SPECIAL REPORT #1: How to Profit – and Keep Profiting – From the GLP-1 Revolution

I frankly think anyone who truly wants to take advantage of this situation would be making a mistake to do it without Dave – who’s been following it for more than a decade… knows what’s really happening inside Eli Lilly and Novo Nordisk… and understands the emerging landscape (and how to profit) better than anyone on the planet outside a handful of scientists. This is a way to maximize your gains… know when to sell.. and understand what’s coming next – and, by itself, could show you hundreds of percent gains, in lower-risk “fortress” stocks.

SPECIAL REPORT #2: What’s Next After GLP-1: The Innovations with Upside as High as 1,000%

Remember – the only question that really matters is, “What’s next?” And Dave’s repeatedly shown readers triple- and quadruple-digit gains by knowing the answer.

These are his FIVE very best ideas today… and could show you 400%... 500%... even 1,000% gains in the next phase of this technological wave.

Even one or two winners like that could not only pay for your research many times over, but change your entire financial outlook.

SPECIAL BONUS: TWO must-see video presentations from our elite 2023 Alliance conference ($2,500 value)

Featuring five more actionable ideas from Dave…

And another five from top editors across Stansberry Research that you won’t find anywhere else.

MEMBER EXCLUSIVE: The Stansberry Venture Technology Handbook

This is the training manual that started it all...

It explains everything you need to know about Dave’s unique approach to the market.

Here you'll learn how Dave can give YOU a venture capital style experience, but with far more liquidity, and with far LESS risk.

Plus, you’ll get full access to the next 12 months of Dave’s Stansberry Venture Technology research issues…

Urgent “buy” and “sell” updates from Dave and his team between issues…

The full archive of every issue and special report we’ve ever published…

And more…

ALL for an unprecedented discount of more than 60% OFF the usual price for a single year of research – just $2,000 today – the LOWEST price we have ever offered a full year of research to Dave's work in our 25-year history.

And remember: You're fully protected by our 30-day, 100% satisfaction guarantee.

You can take the next 30 days to look everything over and still get back every penny you paid in Stansberry Credit if you change your mind.

Credit you can apply to any other research we publish, no matter the price, no questions asked.

I think that’s more than fair.

And I dearly hope you’ll recognize how big this opportunity really is…

And not miss the best and only chance you’ll ever have to accelerate your retirement as the GLP-1 revolution – and everything that follows – reaches millions like Ken.

Thank you for your attention today – we can’t wait to welcome you to Stansberry Venture Technology.

Regards,

Brett Aitken
Publisher, Stansberry Research
March 2024

Your All-Time Low Price: $5,500 $2,000